HRCM
SNDX icon

Hood River Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Hood River Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.1M Buy
2,564,279
+209,994
+9% +$4.37M 0.41% 81
2026
Q1 		$55M Buy
2,354,285
+37,732
+2% +$820K 0.55% 63
2025
Q4 		$48.7M Buy
+2,316,553
New +$40.4M 0.53% 64

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Hood River Capital Management's SNDX Position: Q2 2026 in Review

Hood River Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 8.9% in Q2 2026, buying an estimated $4.37M and bringing the position to 2,564,279 shares worth $56.1M. The position accounts for 0.41% of the portfolio, ranked #81.

Hood River Capital Management first reported a position in SNDX in Q4 2025 and has held it in 3 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Hood River Capital Management held 2,564,279 shares of Syndax Pharmaceuticals worth $56.1M as of Q2 2026.
  • Hood River Capital Management bought 209,994 Syndax Pharmaceuticals shares in Q2 2026, an estimated $4.37M.
  • Syndax Pharmaceuticals made up 0.41% of Hood River Capital Management's portfolio in Q2 2026, its #81 holding.
  • Hood River Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Hood River Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.